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ABSTRACT
Hematopoietic stem cell transplantation may be used to induce a graft-versus-tumor effect against a range of
malignancies. Pretransplantation conditioning regimens vary considerably in their degree of myelosuppression
and immunosuppression, which may result in marked differences in the rate of T-cell engraftment and, as a
consequence, the onset and severity of graft-versus-host disease (GVHD). We have examined the development
of T-cell chimerism and the onset of GVHD following fludarabine and melphalan conditioning in 39 patients
undergoing stem cell allografts frommatched-sibling donors. Cyclosporin and short-course methotrexate were
used as GVHD prophylaxis. Fatal regimen-related toxicity occurred in 4 patients. Rapid T-cell engraftment
was found in all but 1 of the patients assessed, with more than 90% donor T-cell chimerism at 1 month
posttransplantation. Of the evaluable patients, 43% developed grade 2-4 acute GVHD and 87% developed
chronic GVHD (70% extensive). Overall, the combination of fludarabine and melphalan is intensely immu-
nosuppressive, leads to rapid T-cell engraftment and results in substantial toxicity and GVHD, particularly in
heavily pretreated patients.
© 2003 American Society for Blood and Marrow Transplantation
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INTRODUCTION
Engraftment of donor T cells following allogeneic
stem cell transplantation (SCT) is required for induc-
tion of both graft-versus-tumor (GVT) effects and
graft-versus-host disease (GVHD) [1]. Reduced inten-
sity conditioning before SCT has been developed as a
means of exploiting the GVT effect of allogeneic T
cells while mitigating the toxicities and severity of
GVHD associated with myeloablative conditioning
[2,3]. Drawing general conclusions about the kinetics
and clinical consequences of T-cell engraftment fol-
lowing reduced intensity conditioning and SCT is,
however, confounded by the variation both in GVHD
prophylaxis protocols and in the intensity of myelo-
suppression and immunosuppression of the various
regimens. These include low-dose total body irradia-
tion alone [4], in combination with the purine analog
ﬂudarabine [5], or ﬂudarabine in combination with
attenuated doses of alkylating agents such as cyclo-
phosphamide [1,3], busulphan [6], or melphalan (ﬂu-
mel) [7-11]. The reported lower incidence and sever-
ity of GVHD in some of these studies is postulated to
be caused by the veto effect of preserved host regula-
tory T cells and/or the slow evolution to complete
donor chimerism [2,5,12,13]. However, the assess-
ment of donor chimerism posttransplantation has var-
ied, with some groups reporting data on the engraft-
ment of donor CD3 lymphocytes and others on
unfractionated cell populations.
Flu-mel is one of the most commonly used re-
duced-intensity regimens. The results of various pub-
lished studies with this combination of agents are
summarized in Table 1 [7-11]. These studies vary in
the dose and scheduling of ﬂu-mel, the underlying
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Table 1. Published Studies of Allogeneic Transplantation with Fludarabine and Melphalan
Study
Flu-mel Doses
(mg/m2)
No. of
Pts
Median
Age Disease
GVHD
Prophylaxis Donor Stem Cell
Grade 3-4
Nonhematologic
Toxicities
Non-
Relapse
Mortality
Donor Chimerism
Grade
II-IV
aGVHD
Sample/
Lineage
Specificity Result
Martino et
al. [7]
F 150 48 53 Various CSA-MTX Sibling PB Mucositis 25%,
fatal AHF 1 pt
20% at 1 yr BM/no 100% in
33/38
CR pts
32%*
M 140
Giralt et al.
[8]
F 125 78 52 Various tacro-MTX Sibling and
Unrelated
BM or PB 13% 37% at
d100
BM/no† 100%
(median)
49%
M 180 (n  66)
M 140 (n  12)
Giralt et al.
[9]
F 120 M 140
(n  18)
22 51 Myeloma tacro-MTX Sibling and
Unrelated
BM or PB 5% 19% at
d100 40%
at 1 yr
BM/no 100% 46%
F 125 M 180
(n  4)
Chakraverty
et al. [10]
F 150 47 44 Various CSA-
campath
Unrelated BM Not stated 15% at
d100 20%
at 1 yr
BM/no 100% in
29/34
pt
21%
M 140
Perez-Simon
et al. [11]
F 150 78 44 Lymph-prolif CSA-
campath
Sibling PB Not stated 10% at 1 yr 8%
M 140 51 47 CSA-MTX Sibling PB Not stated 20% at 1 yr 43%
Abbreviations: ﬂu-mel, melphalan; CSA, cyclosporin; MTX, methotrexate; tacro, tacrolimus; campath, Campath 1H (alemtuzumab); f, ﬂudarabine; m, melphalan; AHF, acute heart failure;
lymph-prolif, lymphoproliferative disease; PB, peripheral blood; BM, bone marrow; CR, complete remission; pts, patients.
*Includes some patients receiving ﬂudarabine and busulphan.
†12/15 patients fully donor by “lineage-speciﬁc chimerism.”
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disease treated, GVHD prophylaxis, type of donor,
stem cell source, and in the method of assessment of
chimerism. Only 2 studies document the outcome of
matched sibling allografts using peripheral blood pro-
genitor cells (PBPC) alone without T-cell depletion
[7,11]. Both report a 1-year nonrelapse mortality of
20%, with grade 2-4 acute GVHD rates of 32% and
43%, respectively, but neither documents the distri-
bution of GVHD nor evaluates the kinetics of T-cell
and myeloid engraftment separately. In this article we
document the incidence and distribution of GVHD,
together with T-cell and myeloid chimerism analysis
where available, in 39 consecutive patients who un-
derwent SCT from matched-sibling donors using this
regimen.
PATIENTS AND METHODS
The study population consisted of 39 consecutive
patients undergoing SCT with ﬂu-mel conditioning at
either Royal Melbourne Hospital (RMH) or Royal
Brisbane Hospital (RBH); all except 1 received ﬁlgras-
tim-mobilized PBPC from matched sibling donors.
None of the patients were considered appropriate
candidates for full-dose myeloablative allogeneic
BMT. The study protocol was approved by the Ethics
Committee of each hospital, and written informed
consent was obtained from all patients.
Conditioning Regimen and Graft-versus-Host
Disease Prophylaxis
Patients received ﬂudarabine 25 mg/m2 intrave-
nously (IV) on days5 to1 inclusive and melphalan
IV at a dose of either 140 mg/m2 (n  26) or 120
mg/m2 (n  13) on day 1 as pretransplantation
conditioning. GVHD prophylaxis was with IV cyclo-
sporin at 3 mg/kg daily from day 1, followed by oral
cyclosporin postengraftment when tolerated, and IV
methotrexate (MTX) 15 mg/m2 on day 1, and 10
mg/m2 on days 3, 6, and 11. Alterations to the MTX
schedule and the provision of folinic acid rescue were
at the discretion of the treating physician. Nine pa-
tients had the day-11 MTX dose omitted because of
the development of severe mucositis. Three additional
patients received only a single dose of MTX on day 1,
with further doses withheld because of ﬂuid overload
secondary to venocclusive disease, renal impairment,
and mucositis. Overall, 35 patients received folinic
acid rescue. Nine of 10 patients treated at RMH from
December 2000 also received prophylactic pred-
nisolone from day 14 to day 100 as described by Ruutu
et al [14].
Peripheral Blood Progenitor Cell Mobilization and
Infusion
Stem cell mobilization from allogeneic donors was
undertaken with ﬁlgrastim at a dose of 5 to 8 g/kg
subcutaneously twice daily for 4 days with collection
on the ﬁfth day. A minimum PBPC collection of 2 
106 CD34/kg or greater was achieved in 37 donors.
One patient received a combined PBPC and marrow
inoculum because insufﬁcient peripheral blood
CD34 cells were obtained after 2 leukaphereses, and
1 received unmanipulated marrow only because of
failure to mobilize CD34 cells into donor blood to
warrant leukapheresis. One PBPC collection was
cryopreserved. All other PBPC collections and both
marrow collections were infused within 24 hours of
collection and at a minimum of 24 hours after com-
pletion of the melphalan infusion. All transplantations
were T-cell replete.
Supportive Care
Patients were nursed in positive pressure isolation
during conditioning and until neutrophil recovery to
greater than 0.5  109/L. Indwelling silastic IV cath-
eters were inserted in all patients. Anti-infective pro-
phylaxis was provided by aciclovir 200 mg orally every
8 hours or 250 mg IV every 8 hours, ﬂuconazole 200
mg daily orally or IV, and in patients treated at RBH,
norﬂoxacin 200 mg twice daily from day 1 until
neutrophil recovery. In the event of fever during the
neutropenic period, broad-spectrum antibiotics were
initiated empirically as per institutional protocol. Fil-
grastim use was at the discretion of the treating phy-
sician. Following count recovery, trimethoprim-sulfa-
methoxazole orally twice daily on 2 days per week was
initiated for prophylaxis of Pneumocystis carinii infec-
tion. Cytomegalovirus prophylaxis was provided by
ganciclovir 5 mg/kg 3 times a week to day 90 for
RMH patients and by valaciclovir 1000 mg twice daily
to day 90 for patients treated at RBH. In the event of
acute GVHD and/or ongoing steroid use, cytomega-
lovirus prophylaxis was continued until the prednisone
dose was reduced below 20 mg/day.
Chimerism Analysis
Donor chimerism was analyzed in surviving pa-
tients at 1, 3, 6, and 12 months posttransplantation.
Analyses were performed either on unfractionated
marrow, unfractionated peripheral blood or, in the
majority of cases, on the CD3 cell fraction isolated
from peripheral blood by positive Dynal bead (Dynal,
Uppsala, Sweden) selection or by density gradient
separation using the Rosettesep T-cell enrichment kit
(Stemcell Technologies, Canada). In sex-matched
transplantations, DNA extracted from cell samples
was assessed by polymerase chain reaction (PCR)
analysis of microsatellite sequences and compared
with pretransplantation reference samples using estab-
lished techniques [15]. Chimerism analyses performed
by PCR were optimized to detect minor cell popula-
tions of 1% to 5%. In sex-mismatched transplanta-
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tions, chimerism was analyzed by either ﬂuorescent in
situ hybridization (FISH), metaphase banding of mar-
row samples or PCR of peripheral blood samples as
above.
Toxicity and Graft-versus-Host Disease Grading
Toxicity was graded according to Bearman criteria
[16]. Acute and chronic GVHD were scored accord-
ing to published guidelines [17,18]. In patients with
chronic GVHD in whom the extent was difﬁcult to
categorize, those requiring systemic immunosuppres-
sion with at least 2 agents were coded as extensive
disease. Disease status was assessed with a close-out
date of August 31, 2002.
Advanced disease was deﬁned as acute leukemia
beyond ﬁrst complete remission (CR), chronic my-
eloid leukemia beyond ﬁrst chronic phase, myeloma
refractory to treatment or beyond ﬁrst plateau phase,
previously treated myelodysplasia, non-Hodgkins
lymphoma (NHL) primarily refractory or beyond ﬁrst
CR (CR1), or metastatic renal cell carcinoma. All
other disease states were classiﬁed as standard risk.
Statistics
Treatment-related mortality (TRM) was deﬁned
as death from all causes other than progressive disease.
The rates and standard error of TRM at 100 days and
12 months posttransplantation were calculated by
Kaplan-Meier analysis with censoring for 1 patient
who died of progressive disease at day 158.
RESULTS
Table 2 describes patient details and characteris-
tics of the stem cell infusion. Most recipients were
older than 50 years. Median time from transplantation
to the close-out date in surviving patients was 735 days
(range, 54-1380 days). Twenty patients had advanced
disease as deﬁned previously. The majority of patients
had received fewer than 2 prior chemotherapy regi-
mens either because of the primary chemorefractory
nature of the disease (such as acute myeloid leukemia
[AML]), the nonindication for pretransplantation che-
motherapy (such as in chronic myeloid leukemia), or
poor prognostic features of the disease necessitating
early transplantation after attaining CR1. Conversely,
4 of 8 patients with low-grade lymphoproliferative
disorders were heavily pretreated each receiving 3 or
more prior regimens of therapy.
Engraftment
There were no primary graft failures in the 37
patients who survived for at least 14 days posttrans-
plantation. Median time to neutrophils greater than
0.5  109/L was 17 days (range, 12-24 days). In 5
patients the neutrophil nadir did not fall below 0.5 
109/L. Platelet engraftment was also rapid, with a
median time to greater than 20  109/L of 12.5 days
(range, 9-19 days). Four patients did not achieve plate-
let transfusion independence before death as a conse-
quence of venocclusive disease (2 patients), idiopathic
pneumonitis, and multi-organ failure (1 patient each).
Acute Toxicity
Twenty patients developed Bearman grade 2 or 3
toxicity. Eight patients experienced grade 2 or 3 tox-
icity in more than 1 organ (Table 3). Stomatitis was
the most frequently encountered toxicity. Grade 2-3
renal toxicity was seen in 7 patients, attributable in
Table 2. Patient and Stem Cell Details
No. of patients 39
Age (y) 55 (range, 35-68)
Sex: male/female 23/16
No. of prior regimens
0 10
1 19
2 6
3 or more 4
Disease
AML/myelodysplasia 12
Multiple myeloma 9
Low grade NHL/CLL 6
CML 3
Mantle cell NHL 3
Metastatic RCC 2
Myelofibrosis 2
ALL 1
T cell NHL 1
Standard risk disease 19
Advanced disease 20
CD34 cells infused  106/kg 5.2 (1.5-12.5)
CD3 cells infused  107/kg 20.7 (2.2-64.4)*
NOTE. Advanced disease is deﬁned as acute leukemia beyond
ﬁrst CR, CML beyond ﬁrst chronic phase, myeloma refractory to
treatment or beyond ﬁrst plateau, previously treated myelodyspla-
sia, refractory NHL or NHL beyond CR1, or metastatic RCC.
Standard risk is deﬁned as disease other than advanced. Variables
are expressed as median (range).
Abbreviations: NHL, non-Hodgkin lymphoma; CLL, chronic
lymphocytic leukemia; AML, acute myeloid leukaemia; ALL, acute
lymphoblastic leukaemia; CML, chronic myeloid leukaemia; CML,
chronic myelomonoctic leukaemia; RCC, renal cell carcinoma.
*Evaluated in 21 PBPC collections.
Table 3. Bearman Grade Acute, Treatment-Related, Nonhematologic
Toxicity
Grade Stomatitis Gut Cardiac Renal Pulmonary Hepatic MOF
II 9 4 1 6 2 2 —
III 2 0 1 1 1 0 —
IV 0 0 0 2 3 2 1
Total 11 4 2 9 6 4 1
Abbreviation: MOF, multiorgan failure.
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each case to cyclosporin toxicity or amphotericin B.
Cardiac toxicity, identiﬁed by deterioration of left
ventricular ejection fraction on echocardiography, was
seen in 2 patients who experienced clinical signs of
pulmonary oedema. These patients have been previ-
ously reported by our group [19].
Four patients, all with advanced disease, died of
acute organ toxicity. Fatal interstitial pneumonitis oc-
curred early posttransplantation in a patient who had
previously received chest irradiation for multiple my-
eloma. A second patient, aged 68 with refractory T-
cell NHL, died of multi-organ failure before engraft-
ment. Fatal liver failure occurred in 1 patient with
refractory multiple myeloma and in another with met-
astatic renal cell carcinoma. Both patients satisﬁed the
clinical criteria for hepatic venocclusive disease [20],
and portal vein thrombosis was excluded by Doppler
ultrasound scanning; liver biopsies, however, were not
undertaken.
Chimerism Analysis
Five patients did not have samples analyzed for
chimerism, in 3 because of early TRM at days 10, 13,
and 33 and in 2 because of early onset, severe, ulti-
mately fatal, acute GVHD. A total of 152 chimerism
analyses were performed in the remaining 34 patients
(Figure 1). Twenty-four patients had donor chimer-
ism analyzed by PCR (22 on the CD3 cell fraction,
14 on both the CD3 and CD13 fractions, 3 on
unfractionated peripheral blood), and 10 by meta-
phase banding or FISH. Chimerism analysis was avail-
able for 31 patients at 1 month (25 by PCR, 6 by
FISH), and 29 (25 by PCR, 4 by FISH) patients at 3
months post-BMT. All samples showed evidence of
donor chimerism at 1 month, with only 5 patients
showing less than 100% chimerism (28% in 1, be-
tween 91%-96% in 4). With subsequent analyses at 3
months and later, no patient showed loss of donor
chimerism. The lowest recorded level of CD3 donor
chimerism at 3 months in any surviving patient was
51% in a patient with mantle cell lymphoma in whom
full-donor myeloid and lymphoid chimerism was ob-
tained by 12 months without donor leukocyte infusion
(DLI). There was no identiﬁable difference in the
speed or durability of T-cell engraftment between
disease groups.
Chimerism of the CD13 myeloid fraction of pe-
ripheral blood was performed on 14 patients. As was
observed in the CD3 chimerism, donor myeloid en-
graftment was rapid with 13 of 14 patients showing
more than 80% donor chimerism at 1 month (Figure
1). The single patient with less than 30% myeloid
chimerism at 1, 3, and 6 months was the same patient
who demonstrated delayed CD3 cell engraftment.
One additional patient showed a reduction of myeloid
chimerism from 93% at 1 month to 47% at 3 months
with recovery to 95% by 6 months.
Graft-versus-Host Disease
The severity and distribution of both grade 2-4
acute GVHD and chronic GVHD affecting major
target organs are shown in Table 4. Sixteen of 37
patients (43%) surviving to neutrophil engraftment
developed grade 2-4 acute GVHD. The skin and gut
were the major target organs. Hepatic acute GVHD
Figure 1. Donor chimerism analysis following transplantation.
Samples were analyzed at 1, 3, 6, and 12 months posttransplantation
by cytogenetic or PCR analysis as described in the text. At each time
point, the chimerism value for each evaluable patient is given as a
percentage of donor DNA detected in either unselected leukocyte
samples (top panel), the CD3 fraction (middle panel), or CD13
fraction (lower panel). The solid circles show data points for a single
patient with persistently low CD3 and CD13 chimerism. The
number of samples at each time point is shown in parentheses.
Table 4. GvHD in Evaluable Patients after Stem Cell
Transplantation
aGVHD Evaluable  37
CGVHD
Evaluable  30
0 1 2 3 4
Limited
n  5
Extensive
n  21
None 13 — — — — 4
Skin — 3 2 7 1 1 16
Gut — 0 5 3 4 0 8
Liver — 0 0 0 1 0 13
Oral — — — — — 4 14
Abbreviations: aGVHD, acute graft-versus-host disease;
cGVHD, chronic graft-versus-host disease in patients surviving at
least 6 months posttransplantation.
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occurred in only 3 patients, and was fatal in each case.
Overall, 6 patients died of GVHD (15%), 3 within
100 days and 3 in the context of extensive chronic
GVHD, between 4 and 7.5 months posttransplanta-
tion (pneumococcal septicemia, cytomegalovirus coli-
tis, idiopathic pneumonitis).
Of the 30 patients followed for a minimum of 6
months, 26 experienced chronic GVHD, limited in 5
(16%) and extensive in 21 (70%). The latter most
commonly affected skin and liver.
Transplantation-Related Mortality and Disease
Effect
In addition to the patients dying from GVHD or
its complications (n  6) and acute toxicity (n  4), 1
patient died at day 159 from sepsis complicated by
pancytopenia. This patient received 2  106/kg
CD34 cells and 2  108/kg CD3 cells on day 0 and
had 100% donor chimerism at day 120. No further
chimerism data at the time of death are available.
Day-100 TRM was 206% and 1-year TRM was
307%. Treatment-related mortality occurred in 4 of
9 patients with myeloma, 2 from acute organ toxicity
and 2 from GVHD. Both patients who underwent
transplantation for renal cell carcinoma died of trans-
plantation-related toxicity: 1 of venocclusive disease
and 1 of chronic GVHD/sepsis. Conversely, TRM
occurred in only 5 of the remaining 28 patients (18%)
who underwent transplantation for other diseases.
Disease-Free Survival
With a median follow-up of 21 months (range,
3-30 months), 12 of 15 patients who underwent trans-
plantation for AML, myelodysplasia, or chronic my-
eloid leukemia remain alive in CR. One patient, with
chemoresistant secondary AML, has relapsed. Five
patients with AML were in CR1, and 5 with myelo-
dysplasia were previously untreated at the time of
transplantation. Eight of 9 patients who underwent
transplantation for chronic lymphocytic leukemia or
low-grade or mantle cell NHL remain alive and in CR
with a median follow-up of 21 months (range, 10-33
months). Only 1 of the 5 myeloma patients who did
not suffer TRM has relapsed; the remaining 4 are alive
without disease progression (3 have low residual para-
protein levels) at 4, 6, 37, and 46 months posttrans-
plantation.
DISCUSSION
Previous reports have indicated that myeloid and
lymphoid engraftment after reduced-intensity condi-
tioning follow different kinetics, and therefore assess-
ment of total cell chimerism cannot be assumed to
accurately reﬂect lymphoid engraftment [1,21]. In our
series of 39 patients receiving reduced-intensity con-
ditioning with ﬂu-mel, both myeloid and lymphoid
engraftment were prompt and sustained in the ab-
sence of relapse, in all but 1 of the patients surviving
beyond 28 days. An equally rapid and sustained en-
graftment was seen in the analysis of the CD13
myeloid cell fraction. No patient required DLI to
maintain T-cell engraftment.
Table 1 summarizes the results of various pub-
lished studies with the ﬂu-mel combination. While
heterogeneous with respect to dose, disease, GVHD
prophylaxis, donor source, and type of stem cells, they
are relatively consistent with respect to the incidence
of grades 2 to 4 acute GVHD (32%-42% in the
absence of T-cell depletion), a 1-year nonrelapse mor-
tality of 20% to 40%, and a high incidence of com-
plete donor chimerism using unfractionated marrow
at 1 month after transplantation.
Donor T-cell and myeloid engraftment with ﬂu-
mel is considerably more rapid and complete than that
reported previously with most other reduced-intensity
conditioning regimens. In the study by Childs et al.
[1], in which pretransplantation conditioning con-
sisted of ﬂudarabine and cyclophosphamide, donor
T-cell chimerism of more than 90% was observed in 9
of 14 evaluable patients by 30 days posttransplanta-
tion. Evolution to full-donor CD3 T-cell chimerism
occurred in an additional 4 patients by 200 days post-
transplantation, in the context of withdrawal of im-
munosuppression or the addition of DLI.
Using low-dose total body irradiation alone, only
14% of patients were reported to have complete chi-
merism by day 28 [4]. With ﬂudarabine and low-dose
cyclophosphamide and using unfractionated marrow
cells, the median percentage of donor cells at 1 month
posttransplantation was 80% [3]; with the addition of
ﬂudarabine, the median T-cell chimerism at day 28
was 90% with the caveat that most of the latter group
had undergone a prior autologous transplantation [5].
The rapid development of virtually complete do-
nor T-cell and myeloid chimerism observed in the
current study reﬂects the profound immunosuppres-
sive and potentially myeloablative effects of ﬂu-mel.
Consistent with this, the morbidity and mortality
caused by GVHD in this study was signiﬁcant. Of the
evaluable patients, 43% experienced grade 2-4 acute
GVHD and 70% experienced extensive chronic
GVHD, which was fatal in 15%. These results are
consistent with other series using ﬂu-mel and cyclo-
sporine-MTX as GVHD prophylaxis (Table 1). No
differences in either time to onset or the severity of
GVHD could be seen between the various types of
diseases transplanted.
Grade 2-3 nonhematologic toxicity was observed
in the majority of patients, with mucositis, gut toxic-
ity, and renal toxicity predominating. The high inci-
dence of mucositis in part may reﬂect the use of MTX
as GVHD prophylaxis. Overall, TRM was substantial,
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with 11 patients (28%) dying, 4 from acute organ
toxicity, 6 from GVHD, and 1 from late onset sepsis.
As has been described with myeloablative condition-
ing regimens, patients who underwent transplantation
for multiple myeloma showed a disproportionately
high TRM [22], indicating that despite the reduced
intensity of ﬂu-mel these patients remain vulnerable
to life-threatening toxicity. Conversely, patients with
acute or chronic myeloid malignancies or chronic B-
cell NHL/chronic lymphocytic leukemia experienced
lower levels of grade 2-3 toxicity, and, in this series, no
acute TRM. These results are consistent with those
illustrated in Table 1, in which patients with myeloma
appeared to have a higher TRM than those who un-
derwent transplantation with ﬂu-mel for other dis-
eases [9].
In our experience, the combination of aggressive
conditioning and GVT effects has resulted in a low
relapse rate in patients surviving more than 100 days
after transplantation. These results are consistent with
those of Martino et al. [7], where the incidence of
disease progression in patients with chemosensitive
disease before transplantation was approximately
10%, and of Perez-Simon et al. [11], in which a com-
bination of conditioning and GVHD prophylaxis sim-
ilar to ours resulted in disease progression in only
10% of patients with chronic lymphoproliferative dis-
eases, the majority of whom were not in remission at
the time of transplantation.
In summary, our ﬁndings show that the ﬂu-mel
combination is an aggressive regimen that results in
signiﬁcant organ toxicity, particularly in previously
heavily treated patients. This combination of chemo-
therapy is sufﬁciently immunosuppressive and myelo-
suppressive to allow complete or near complete donor
chimerism within 1 month of transplantation without
the need for additional DLI. The rapid engraftment of
donor T cells, coupled with signiﬁcant mucosal tox-
icity, resulted in a substantial risk of aGVHD. Nev-
ertheless, the combination of tumor reduction by ﬂu-
mel and GVT effects produced a low rate of relapse,
even in patients with advanced disease. Overall, our
ﬁndings indicate that the clinical pattern of a trans-
plantation after conditioning with ﬂu-mel is not dis-
similar to that of a conventional myeloablative SCT.
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